CRO Leadership
Anthony S. Chilton, President and Chief Executive Officer of BASi, puts forward three key observations post the commercial impact of the economy in the CRO industry.
Anthony S. Chilton, President and Chief Executive Officer of BASi, puts forward three key observations post the commercial impact of the economy in the CRO industry.
In addition to being more economically viable for companies, a critical advantage of this approach is that it offers greater consistency for clinical trials, while significantly increasing data quality – explains Amy Furlong, Executive Vice President, Cardiac Safety Operations of ERT.
Dr. Betsy Hughes Formella of Bioskin GmbH explains why the development and validation of appropriate methodologies to determine the rate and extent to which a topically applied drug reaches its site of action within the skin is one of the biggest challenges in dermatological research today.
Eric Halioua Etienne and Marc Sokal of Promethera Biosciences explain that cell therapy has been identified as the best alternative tool to overcome scarcity of organ donation.
Pichia expression cells can furnish yields of more than 10g/L of secreted recombinant target protein. Dr Roland Weis and Dr Thomas Purkarthofer of VTU Technology GmbH argue that there are many aspects and factors influencing expression levels which have to be tuned properly in order to obtain a high performance expression strain.
In this article, Richard Houghton of Quotient Bioresearch discusses the benefit of androgynous assay validation.
The development of scientific excellence translate into accompaniment of R&D project-holders during calls launched by the Walloon region. These R&D projects bring togethet at least two operators from the industrial sector and two partners from the academic world.
In this observational study of the US medical device industry Saurabh Awasthi and Nikhil Bhanagar of Kinapse explain that while focus on innovative research and development (R&D) should be the top priority of device companies, the industry also needs to reassess their strategic focus while streamlining their regulatory and clinical operations.
Simon Coles, the co-founder and Chief Technical Officer of Amphora Research Systems, explains that improving return on investment starts with people and the deployment of information systems to help people do their work; the extent to which the system is used effectively determines the ROI achieved.
This article proposes a carbon neutral vision for the future of the chemical industry in alingment with a carbon neutral future under the Kyoto Protocol.